Industry | 制造业 | ||||||||||||||||||||||||
Company Introduction | 普莱柯生物工程股份有限公司是以研发、生产、经营兽用生物制品及药品为主业的高新技术企业,创新能力与综合实力位居行业前列。拥有洛阳惠中生物技术有限公司、洛阳惠中兽药有限公司、河南新正好生物工程有限公司、洛阳中科科技园有限公司、普莱柯(南京)生物技术有限公司、洛阳惠中动物保健有限公司、洛阳乐宠健康科技有限公司7家全资子公司。公司为上交所挂牌上市企业(股票代码:603566)、中国畜牧兽医学会副理事长单位、中国兽药协会副会长单位,国家技术创新示范企业。系国家兽药产业技术创新联盟、国家生猪产业技术创新联盟、国家动物健康管理与食品安全等3个创新联盟副理事长单位。 普莱柯始终将自主创新和集成创新作为企业发展的源动力,拥有经国家科技部批准组建的国家兽用药品工程技术研究中心,经国家发改委、科技部等五部委联合认定的国家认定企业技术中心及经国家发改委批准认定的动物传染病诊断试剂与疫苗开发国家地方联合工程实验室,并设有博士后科研工作站,研发场所面积近20000平米,以博士、硕士为主体的技术研发人员200余人;先后与中国农业科学院哈尔滨兽医研究所、中国农业科学院兰州兽医研究所、军事医学科学院军事兽医研究所、中国农业大学、南京农业大学等机构建立了广泛的产学研合作关系。公司始终保持高强度的研发投入,近年来,研发费用占营业收入的比重达10%以上。 基于公司强大的创新能力,依托高标准、高起点建设的研发平台,公司先后承担了国家科技部863计划、国家科技支撑计划、国家发改委高技术产业化专项、河南省重大科技专项、洛阳市科技重大专项等国家、省、市级各类重大科技项目近40项;截至2023年6月,累计取得新兽药证书63项、获得认证国家重点新产品4项;申请发明专利546项,取得发明专利授权312项,其中获得国际发明专利32项,获国家、省、市科技成果奖20余项,中国专利优秀奖3项,已成为国内动物药品行业科技创新领先的企业。 近年来,公司在反向遗传技术、细菌人工染色体技术、原核及真核表达技术、高密度细胞悬浮培养工艺技术、高密度发酵及抗原提取浓缩纯化技术等产业化技术方面不断取得重大突破,在基因工程疫苗、大环内酯类动物专用抗生素等产品结构创新方面居行业领先水平。其中,鸡新支流(Re-9株)基因工程三联灭活疫苗引领我国H9亚型禽流感疫苗进入基因工程疫苗时代;历时7年成功研发的纯病毒样颗粒猪圆环病毒2型基因工程亚单位疫苗已经上市,引领行业猪圆环病毒疫苗的迭代升级;2019年,变异毒株猪伪狂犬病灭活疫苗(HN1201-ΔgE株)普伪净顺利上市,对我国猪伪狂犬病的防控及净化将做出积极的贡献;2022年,猪瘟病毒E2蛋白重组杆状病毒灭活疫苗(Rb-03株)稳柯净震撼上市,引领猪瘟防控新时代;2023年,猪圆环病毒2型、猪肺炎支原体二联灭活疫苗欣圆支荣耀上市,为我国猪病的深度防控和全面净化提供强大的技术和产品支撑。 普莱柯坚持以“金牌品质,造福人类”为宗旨,奉行“创新成就未来”的发展理念,恪守“正派稳健经营”的经营方略,发扬“诚信务实、永创一流”的企业精神,高起点、高标准地从事兽用新疫苗和新兽药的研究、生产与推广,致力于打造中国动保行业的世界性品牌! | ||||||||||||||||||||||||
Main Business | 兽用生物制品、化学药品及中兽药的研发、生产及销售。 | ||||||||||||||||||||||||
Legal Representative | 胡伟 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 赵锐 | ||||||||||||||||||||||||
Solicitors | 北京德恒律师事务所 | ||||||||||||||||||||||||
Auditors | 立信会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 0379-63282386 | ||||||||||||||||||||||||
Fax No | 0379-63282386 | ||||||||||||||||||||||||
Website | www.pulike.com.cn | ||||||||||||||||||||||||
ir@pulike.com.cn | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 18/05/2015 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ 0.500 | ||||||||||||||||||||||||
DPS(RMB)* | ¥ 0.700 | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 7.718 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 4.073B |
![]() |
Only Chinese content is avaliable |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |